Post-operative concurrent chemoradiation therapy using oral uracil-tegafur versus weekly intravenous fluorouracil for locally advanced rectal cancer

Chen Hsi Hsieh, Yu Jen Chen, Kou Hwa Chang, Hsi Hsien Hsu, Chien Kuo Liu, Shih Kai Hung, Hong Wen Chen, Yuen Liang Lai, Tzu Chi Hsu

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: This prospective, nonrandomized study was conducted to compare the efficacy and toxicity of post-operative concurrent chemoradiation therapy (CCRT) using daily oral uracil-tegafur plus leucovorin (UFUR/LV) vs. weekly intravenous fluorouracil plus leucovorin (5-FU/LV) in patients with locally advanced rectal cancer. Materials and Methods: From November 1996 through December 2004, 30 patients with stage II or III rectal cancer were enrolled. Either 5-FU (400 to 450 mg/m2) plus LV (80 to 100 mg/m2) weekly or oral UFUR (250 to 300 mg/m2/d) plus oral LV (30 to 45 mg/m2/d) were given during radiotherapy. Radiation (50.4 to 60.4 Gy) was delivered to the tumor bed in 28 - 33 fractions. Results: The mean survival, 2-year overall survival and disease-free survival were 36 months vs. 30 months, 68% vs. 66% and 55% vs. 50%, (p>0.05), in the UFUR/LV and 5-FU/LV groups, respectively. There were no treatment-related deaths or grade 4 toxicity in either group. Grade 3 dermatitis, gastrointestinal and hematologic toxicity were noted in the 5-FU/LV group. Conclusion: Because of a similar survival rate and lower toxicity, oral UFUR/LV is suggested as an alternative regimen to intravenous 5-FU/LV in post-operative CCRT of locally advanced rectal cancer.

Original languageEnglish
Pages (from-to)3709-3715
Number of pages7
JournalAnticancer Research
Volume26
Issue number5 B
Publication statusPublished - Sep 2006
Externally publishedYes

Fingerprint

Tegafur
Uracil
Rectal Neoplasms
Fluorouracil
Leucovorin
Therapeutics
Survival
Dermatitis
Disease-Free Survival
Radiotherapy
Survival Rate
Prospective Studies
Radiation
Neoplasms

Keywords

  • Chemoradiation
  • Fluorouracil (5-FU)
  • Leucovorin (LV)
  • Uracil-tegafur (UFUR)

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Hsieh, C. H., Chen, Y. J., Chang, K. H., Hsu, H. H., Liu, C. K., Hung, S. K., ... Hsu, T. C. (2006). Post-operative concurrent chemoradiation therapy using oral uracil-tegafur versus weekly intravenous fluorouracil for locally advanced rectal cancer. Anticancer Research, 26(5 B), 3709-3715.

Post-operative concurrent chemoradiation therapy using oral uracil-tegafur versus weekly intravenous fluorouracil for locally advanced rectal cancer. / Hsieh, Chen Hsi; Chen, Yu Jen; Chang, Kou Hwa; Hsu, Hsi Hsien; Liu, Chien Kuo; Hung, Shih Kai; Chen, Hong Wen; Lai, Yuen Liang; Hsu, Tzu Chi.

In: Anticancer Research, Vol. 26, No. 5 B, 09.2006, p. 3709-3715.

Research output: Contribution to journalArticle

Hsieh, CH, Chen, YJ, Chang, KH, Hsu, HH, Liu, CK, Hung, SK, Chen, HW, Lai, YL & Hsu, TC 2006, 'Post-operative concurrent chemoradiation therapy using oral uracil-tegafur versus weekly intravenous fluorouracil for locally advanced rectal cancer', Anticancer Research, vol. 26, no. 5 B, pp. 3709-3715.
Hsieh, Chen Hsi ; Chen, Yu Jen ; Chang, Kou Hwa ; Hsu, Hsi Hsien ; Liu, Chien Kuo ; Hung, Shih Kai ; Chen, Hong Wen ; Lai, Yuen Liang ; Hsu, Tzu Chi. / Post-operative concurrent chemoradiation therapy using oral uracil-tegafur versus weekly intravenous fluorouracil for locally advanced rectal cancer. In: Anticancer Research. 2006 ; Vol. 26, No. 5 B. pp. 3709-3715.
@article{b55a611996014d0d89957dd840f7872c,
title = "Post-operative concurrent chemoradiation therapy using oral uracil-tegafur versus weekly intravenous fluorouracil for locally advanced rectal cancer",
abstract = "Background: This prospective, nonrandomized study was conducted to compare the efficacy and toxicity of post-operative concurrent chemoradiation therapy (CCRT) using daily oral uracil-tegafur plus leucovorin (UFUR/LV) vs. weekly intravenous fluorouracil plus leucovorin (5-FU/LV) in patients with locally advanced rectal cancer. Materials and Methods: From November 1996 through December 2004, 30 patients with stage II or III rectal cancer were enrolled. Either 5-FU (400 to 450 mg/m2) plus LV (80 to 100 mg/m2) weekly or oral UFUR (250 to 300 mg/m2/d) plus oral LV (30 to 45 mg/m2/d) were given during radiotherapy. Radiation (50.4 to 60.4 Gy) was delivered to the tumor bed in 28 - 33 fractions. Results: The mean survival, 2-year overall survival and disease-free survival were 36 months vs. 30 months, 68{\%} vs. 66{\%} and 55{\%} vs. 50{\%}, (p>0.05), in the UFUR/LV and 5-FU/LV groups, respectively. There were no treatment-related deaths or grade 4 toxicity in either group. Grade 3 dermatitis, gastrointestinal and hematologic toxicity were noted in the 5-FU/LV group. Conclusion: Because of a similar survival rate and lower toxicity, oral UFUR/LV is suggested as an alternative regimen to intravenous 5-FU/LV in post-operative CCRT of locally advanced rectal cancer.",
keywords = "Chemoradiation, Fluorouracil (5-FU), Leucovorin (LV), Uracil-tegafur (UFUR)",
author = "Hsieh, {Chen Hsi} and Chen, {Yu Jen} and Chang, {Kou Hwa} and Hsu, {Hsi Hsien} and Liu, {Chien Kuo} and Hung, {Shih Kai} and Chen, {Hong Wen} and Lai, {Yuen Liang} and Hsu, {Tzu Chi}",
year = "2006",
month = "9",
language = "English",
volume = "26",
pages = "3709--3715",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "5 B",

}

TY - JOUR

T1 - Post-operative concurrent chemoradiation therapy using oral uracil-tegafur versus weekly intravenous fluorouracil for locally advanced rectal cancer

AU - Hsieh, Chen Hsi

AU - Chen, Yu Jen

AU - Chang, Kou Hwa

AU - Hsu, Hsi Hsien

AU - Liu, Chien Kuo

AU - Hung, Shih Kai

AU - Chen, Hong Wen

AU - Lai, Yuen Liang

AU - Hsu, Tzu Chi

PY - 2006/9

Y1 - 2006/9

N2 - Background: This prospective, nonrandomized study was conducted to compare the efficacy and toxicity of post-operative concurrent chemoradiation therapy (CCRT) using daily oral uracil-tegafur plus leucovorin (UFUR/LV) vs. weekly intravenous fluorouracil plus leucovorin (5-FU/LV) in patients with locally advanced rectal cancer. Materials and Methods: From November 1996 through December 2004, 30 patients with stage II or III rectal cancer were enrolled. Either 5-FU (400 to 450 mg/m2) plus LV (80 to 100 mg/m2) weekly or oral UFUR (250 to 300 mg/m2/d) plus oral LV (30 to 45 mg/m2/d) were given during radiotherapy. Radiation (50.4 to 60.4 Gy) was delivered to the tumor bed in 28 - 33 fractions. Results: The mean survival, 2-year overall survival and disease-free survival were 36 months vs. 30 months, 68% vs. 66% and 55% vs. 50%, (p>0.05), in the UFUR/LV and 5-FU/LV groups, respectively. There were no treatment-related deaths or grade 4 toxicity in either group. Grade 3 dermatitis, gastrointestinal and hematologic toxicity were noted in the 5-FU/LV group. Conclusion: Because of a similar survival rate and lower toxicity, oral UFUR/LV is suggested as an alternative regimen to intravenous 5-FU/LV in post-operative CCRT of locally advanced rectal cancer.

AB - Background: This prospective, nonrandomized study was conducted to compare the efficacy and toxicity of post-operative concurrent chemoradiation therapy (CCRT) using daily oral uracil-tegafur plus leucovorin (UFUR/LV) vs. weekly intravenous fluorouracil plus leucovorin (5-FU/LV) in patients with locally advanced rectal cancer. Materials and Methods: From November 1996 through December 2004, 30 patients with stage II or III rectal cancer were enrolled. Either 5-FU (400 to 450 mg/m2) plus LV (80 to 100 mg/m2) weekly or oral UFUR (250 to 300 mg/m2/d) plus oral LV (30 to 45 mg/m2/d) were given during radiotherapy. Radiation (50.4 to 60.4 Gy) was delivered to the tumor bed in 28 - 33 fractions. Results: The mean survival, 2-year overall survival and disease-free survival were 36 months vs. 30 months, 68% vs. 66% and 55% vs. 50%, (p>0.05), in the UFUR/LV and 5-FU/LV groups, respectively. There were no treatment-related deaths or grade 4 toxicity in either group. Grade 3 dermatitis, gastrointestinal and hematologic toxicity were noted in the 5-FU/LV group. Conclusion: Because of a similar survival rate and lower toxicity, oral UFUR/LV is suggested as an alternative regimen to intravenous 5-FU/LV in post-operative CCRT of locally advanced rectal cancer.

KW - Chemoradiation

KW - Fluorouracil (5-FU)

KW - Leucovorin (LV)

KW - Uracil-tegafur (UFUR)

UR - http://www.scopus.com/inward/record.url?scp=33750716502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750716502&partnerID=8YFLogxK

M3 - Article

C2 - 17094389

AN - SCOPUS:33750716502

VL - 26

SP - 3709

EP - 3715

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 5 B

ER -